We are pleased to announce the completed renovation of TB Online – a website for activists, patients, healthcare workers, and researchers to learn more about tuberculosis (TB).

The analysis illustrates important differences in costs of anti-TB medications and highlights potential areas of intervention for initiatives aimed at accelerating progress towards achieving global TB targets, through increasing access to affordable anti-TB medications.

Concerns are growing over the disruption in treatment for people living with HIV and tuberculosis in Eastern Ukraine where fighting in the rebel-controlled territories of Donetsk and Luhansk has interrupted crucial medical supplies.

For World TB Day 2015, partners will continue to call for a global effort to find, treat and cure all people with TB and accelerate progress towards the bold goal of ending TB by 2035.

The affected communities should no longer be passive recipients of care but valuable partners with decision-making power in choices and policies that affect them.

In children with latent tuberculosis, 3 months of combined therapy with isoniazid and rifapentine is safe and as effective as 9 months of isoniazid alone.

The article details the advocacy campaign that led Sanofi to decrease the price of TB drug rifapentine by 57% in the United States.

The document is designed to facilitate community reviews of clinical trials protocols and to ensure community participation in protocol development.

Doctors believe there is greater drug resistance and complexity of TB, which disproportionally affects immigrants.

Shortages place some 50,000 patients at risk.